Last updated: July 29, 2026
LEO Pharma A/S v. Actavis Laboratories UT, Inc. (1:16-cv-00333) Litigation Summary and Patent-Infringement Analysis
LEO Pharma A/S sued Actavis Laboratories UT, Inc. in the U.S. District Court for the District of Delaware in Case No. 1:16-cv-00333 in 2016. The dispute is a Delaware patent-infringement case tied to LEO’s branded dermatology portfolio and Actavis’s abbreviated pathway launch efforts. The docket captures a typical Hatch-Waxman structure: LEO asserts one or more Orange-Book-listed patents and Actavis responds with non-infringement, invalidity, and/or statutory defenses, usually connected to a Paragraph IV certification and FDA NDA/ANDA advancement.
What matters for business action: this case is best treated as an “estate and exclusivity posture” signal for LEO in the specific product-family at issue, because it reflects LEO’s willingness to enforce formulation and/or method-of-use claims in Delaware against an ANDA filer. The case should also be mapped to (1) Orange Book listings and (2) the ANDA’s Paragraph IV timeline to quantify generic entry risk and potential launch sequencing.
What is the case background for LEO Pharma A/S v. Actavis Laboratories UT, Inc. | 1:16-cv-00333?
Case details (caption-level):
- Parties: LEO Pharma A/S (plaintiff) vs. Actavis Laboratories UT, Inc. (defendant)
- Court / docket: U.S. District Court, District of Delaware
- Case number: 1:16-cv-00333
- Filing year: 2016 (as indicated by case number timeline and standard reporting)
Procedural posture typical for this docket type:
- LEO files a patent infringement complaint under 35 U.S.C. § 271(e)(2) tied to an ANDA submission.
- Actavis responds with defenses attacking claim scope and/or validity (invalidity under 35 U.S.C. § 102/103/112; non-infringement under claim construction).
- The case proceeds through case management orders, claim construction, summary judgment motions, and trial (or settlement), depending on the factual and litigation posture.
Business read-through:
- Delaware is the default venue for Hatch-Waxman patent fights. A filed suit by LEO implies the asserted patents were Orange-Book listed for the referenced drug and that Actavis’s ANDA included a certification enabling infringement exposure.
Which LEO product and which asserted patents were at issue?
This cannot be stated accurately from the information provided. A complete and accurate litigation analysis requires the specific asserted patent numbers, the drug strength/dosage form, and the Orange Book mapping for the ANDA referenced in the complaint.
Because those elements are not present in the prompt, a precise patent-by-patent litigation analysis is not permitted here.
What patents were asserted by LEO Pharma in 1:16-cv-00333, and how were they categorized (formulation vs method-of-use vs device delivery)?
Answer (high-confidence structural classification only):
- In LEO’s typical dermatology patent portfolios, asserted patents often fall into:
- Formulation patents (composition, excipients, concentration ranges, stabilized systems, particle or vehicle systems)
- Use or method-of-use patents (treatment regimens, dosing schedules, patient subsets)
- Manufacturing/process patents (less common than formulations in some LEO estates but frequent in certain portfolios)
What cannot be stated:
- The exact patents and which category they belong to in this specific suit.
How does this litigation relate to Hatch-Waxman Paragraph IV certifications and FDA ANDA approval timing?
General Hatch-Waxman linkage (what the case implies):
- A suit filed in 2016 by a brand owner against an ANDA filer typically follows:
- An ANDA submission containing a Paragraph IV certification for one or more Orange-Book patents
- A 45-day window in which the brand can sue to trigger the automatic stay of FDA approval (unless exceptions apply)
- Subsequent litigation while FDA approval remains blocked or enters a post-stay posture
Business linkage that should be applied to make decisions:
- Identify the ANDA number for Actavis’s product referenced in the complaint.
- Match the ANDA’s paragraph IV certifications to the exact patent numbers asserted in Delaware.
- Tie settlement or judgment dates to likely generic launch windows.
Without the ANDA number and asserted patent list, the timeline cannot be quantified.
What were the core legal arguments for non-infringement and invalidity in this case?
Typical argument map for Delaware Hatch-Waxman disputes:
- Claim construction: disputes over key claim terms controlling formulation composition, stability parameters, dosing language, or method steps.
- Non-infringement: argument that Actavis’s proposed ANDA product does not meet one or more claim elements (e.g., different excipient system, concentration range, process parameters, or method timing).
- Invalidity: anticipation or obviousness based on prior art references; indefiniteness or inadequate enablement arguments for certain dependent claim structures; sometimes written description attacks.
- Statutory defenses: if raised, defenses tied to patent type, prosecution history, or FDA regulatory status.
What cannot be stated:
- The exact arguments and which were successful, because the factual record and motion outcomes are not included in the prompt.
Did LEO and Actavis settle, and what does settlement usually mean for generic launch risk?
Answer (structural):
- In many Actavis-vs-brand Hatch-Waxman cases, settlement is used to resolve claim scope and design-around issues and to permit launch at an agreed date, potentially with:
- a license with payment terms (reverse or otherwise),
- a partial dismissal,
- or a covenant not to sue coupled with a launch date.
What cannot be stated:
- Whether there was a settlement here, the terms, and whether there was a dismissed-with-prejudice posture or trial.
What is the procedural timeline for 1:16-cv-00333 (key events, motions, claim construction, judgment dates)?
A litigation timeline requires docket event data (e.g., complaint filing date, answer, claim construction order, summary judgment rulings, trial date, final judgment, or settlement order). That information is not provided in the prompt, so a factual timeline cannot be created without risking inaccuracy.
How strong is LEO’s patent estate implied by bringing this Delaware suit against Actavis?
What can be concluded from filing alone:
- LEO deemed the patents commercially enforceable enough to litigate in Delaware.
- The asserted claims likely had at least a plausible infringement theory against Actavis’s proposed ANDA product.
What cannot be concluded:
- Claim strength, likelihood of injunction, or likely validity outcomes without:
- the asserted claim set,
- claim construction outcomes,
- infringement analysis,
- prior art positions,
- and the final disposition.
What generic entry risks existed for Actavis after 1:16-cv-00333 was filed?
Entry-risk framework (without product-specific mapping):
- Filing triggers the brand’s enforcement window and can delay FDA approval if statutory prerequisites are satisfied.
- Post-suit outcomes typically shift entry risk based on:
- motion outcomes (validity and infringement),
- settlement dates,
- and any remaining asserted patents not resolved.
What cannot be stated:
- Whether Actavis ultimately launched, when, and for which strength/form.
How does this case compare with other LEO Pharma v. generic challenges in Delaware (Actavis or peers)?
Comparative analysis requires at least one of:
- a list of similar cases,
- identical/overlapping LEO patents and drug products,
- consistent settlement/claim outcomes.
None of those inputs are included, so comparison would be speculative.
What FDA regulatory status and Orange Book listings should be checked for the drug tied to 1:16-cv-00333?
A complete Orange Book and regulatory analysis requires:
- drug name and NDA/ANDA pairing,
- Orange Book patent numbers,
- listed expiration dates and regulatory exclusivities.
Those are not present in the prompt.
Key Takeaways
- LEO Pharma A/S brought a Delaware Hatch-Waxman style patent infringement case against Actavis Laboratories UT, Inc. in 1:16-cv-00333 in 2016.
- The filing indicates Orange Book patent enforcement tied to Actavis’s ANDA pathway and creates a measurable generic entry delay or leverage for settlement.
- A patent-by-patent and timeline analysis cannot be completed from the provided information because the asserted patent numbers, product identity, and docket outcomes are not included.
FAQs
- What court issued the decision in LEO Pharma A/S v. Actavis Laboratories UT, Inc. (1:16-cv-00333)?
- Does 1:16-cv-00333 involve an ANDA Paragraph IV certification?
- What types of claims do LEO Pharma typically assert in dermatology Hatch-Waxman cases?
- How does settlement in Delaware Hatch-Waxman cases usually affect FDA approval timing?
- What Orange Book information should be mapped to calculate generic launch risk after a suit like 1:16-cv-00333?
References
- (Case citation not provided in the prompt; no additional sources were included.)
